Barnes P J
Department of Thoracic Medicine, National Heart and Lung Institute, London, UK.
J Intern Med. 1992 May;231(5):453-61. doi: 10.1111/j.1365-2796.1992.tb00960.x.
It has now become apparent that asthma, even in its mildest clinical manifestation, is a chronic inflammatory condition of the airways. There have been important advances in understanding the special features of inflammation in asthmatic airways and the role of critical inflammatory cells such as mast cells (important in the acute inflammatory response) and eosinophils, macrophages and T-lymphocytes (involved in the chronic inflammatory response). Many inflammatory mediators have been implicated in asthma, and the development of mediator antagonists suggests that sulphidopeptide leukotrienes may play an important role in bronchoconstrictor responses. Cytokines released from many different cells in the airways are likely to be important in orchestrating and perpetuating the chronic inflammatory response. Chronic inflammation has effects on airway vessels, mucus secretion, smooth muscle and nerves, with evidence to suggest that there are structural changes which may lead to persistent airway abnormalities. The therapeutic implication of these new discoveries is that much earlier use of anti-inflammatory treatments (such as inhaled steroids) is preferable to reliance on bronchodilators which do not control the underlying inflammatory process.
目前已明确,哮喘即便在其最轻微的临床表现中,也是一种气道慢性炎症性疾病。在理解哮喘气道炎症的特殊特征以及关键炎症细胞(如在急性炎症反应中起重要作用的肥大细胞,以及参与慢性炎症反应的嗜酸性粒细胞、巨噬细胞和T淋巴细胞)的作用方面,已经取得了重要进展。许多炎症介质与哮喘有关,介质拮抗剂的研发表明,硫肽白三烯可能在支气管收缩反应中起重要作用。气道中许多不同细胞释放的细胞因子可能在协调和维持慢性炎症反应中起重要作用。慢性炎症会影响气道血管、黏液分泌、平滑肌和神经,有证据表明存在可能导致持续性气道异常的结构变化。这些新发现的治疗意义在于,尽早使用抗炎治疗(如吸入性类固醇)比依赖不能控制潜在炎症过程的支气管扩张剂更为可取。